SCHEMBL1720529

SCHEMBL1720529

CCOC(=O)N1CCC(c2nn(C)c(N)c2-c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
TSHR P16473 2/20 0.51
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 2/20 0.47
HSD17B10 Q99714 4/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
POLB P06746 1/20 0.46
BRD4 O60885 1/20 0.45
USP2 O75604 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.44
NOS2 P35228 1/20 0.44
CHRM4 P08173 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720599 0.89 HSD17B10 (0.52) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1720137 0.80 ALDH1A1 (0.48) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1721044 0.78 MAPK14 (0.41) HSD17B10KDM4EHPGDMAPK1HTT
SCHEMBL1720176 0.73 KDM4E (0.46) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL4724261 0.72 PDE4B (0.45) HTT
SCHEMBL1721167 0.71 ALDH1A1 (0.46) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1720065 0.71 PARP1 (0.71) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL4705226 0.70 GAA (0.58) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL17363126 0.69 CHRM2 (0.54) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL1720231 0.69 BRD4 (0.44) ALDH1A1MEN1KMT2AHSD17B10BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 ALDH1A1 169/4885TSHR 4866/4885MAPT 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.